Cingulate INC 8-K filings

Cingulate Inc. announced its second quarter 2026 financial results, highlighting $28.4 million in cash, progress on CTx-1301 manufacturing, and a new patent, while navigating a delayed NDA resubmission.

Cingulate Inc. announced the elimination of its Chief Legal Officer position, with Nilay Patel departing effective August 3, 2026.

Cingulate Inc. announced key stockholder approvals at its 2026 Annual Meeting, including an amendment to its equity incentive plan and changes to its Board of Directors structure.

Cingulate Inc. announced its inclusion in the Russell 3000E Index and an extension of its Chief Medical Officer's trial employment period.

Cingulate Inc. announced the issuance of a U.S. patent for its lead ADHD asset, CTx-1301, extending exclusivity for its formulation and method of use through December 2042.

Cingulate Inc. announced the FDA issued a Complete Response Letter for its ADHD drug candidate CTx-1301, citing CMC-related requests without clinical concerns.

Cingulate Inc. announces board size reduction and director re-appointments ahead of the 2026 Annual Meeting.

Cingulate Inc. announced its first quarter 2026 financial results, highlighting a strengthened balance sheet with $25.9 million in cash and cash equivalents, and provided an update on its lead ADHD asset, CTx-1301, with regulatory engagement and commercial readiness efforts ongoing.

Cingulate Inc. entered into an At-the-Market Sales Agreement for up to $100 million in common stock and received shareholder approval for prior equity issuances.

Cingulate Inc. announced a U.S. patent allowance and European patent grant for its lead ADHD drug CTx-1301, alongside a $12 million private placement, as its NDA for CTx-1301 undergoes FDA review.

Cingulate Inc. successfully closed a $12 million private placement and appointed Jeff Hargroves to its Board of Directors, bolstering its financial position and governance.

Cingulate Inc. announced the completion of a $6.5 million private placement tranche and several debt-for-equity conversions.

Cingulate Inc. announced a private placement raising approximately $12 million through the sale of common stock, convertible preferred stock, and warrants, with new board representation for a key investor.

Cingulate Inc. increased its At-The-Market offering capacity to $31.9 million and filed a prospectus supplement for an additional $8.84 million in common stock.

Cingulate Inc. announced a series of unregistered equity issuances to lenders in exchange for approximately $1.85 million in debt.

Cingulate Inc. announced the reinstatement of Shane Schaffer as Chief Executive Officer following the resolution of a personal legal matter.

Cingulate Inc. announced FDA acceptance of its CTx-1301 NDA with a May 2026 PDUFA date, completed a $6 million financing, appointed a Chief Commercial Officer, and reported increased Q3 2025 net loss.

Cingulate Inc. announced a $6 million financing deal and the appointment of Bryan Downey as Chief Commercial Officer to prepare for the potential launch of CTx-1301.

The FDA has accepted Cingulate Inc.'s New Drug Application for CTx-1301, its lead ADHD candidate, setting a PDUFA target action date of May 31, 2026.

Cingulate Inc. stockholders approved the issuance of over 20% of common stock to Lincoln Park Capital Fund, LLC, securing a key funding mechanism.

Cingulate Inc. issued over 325,000 shares of common stock to lenders between July and September 2025, converting portions of outstanding debt into equity.

Cingulate Inc. announced significant executive leadership changes, including a new Executive Chairman, CEO administrative leave, and a separation agreement with a former employee.

Cingulate Inc. submitted its New Drug Application for lead ADHD asset CTx-1301 to the FDA and reported increased net loss and expenses for the second quarter of 2025.

Cingulate Inc. announced its CEO, Shane Schaffer, was charged with aggravated domestic battery, leading to his administrative leave and the appointment of interim leadership.

Cingulate Inc. announced the termination of employment for its Executive Vice President and Chief Operating Officer, Laurie A. Myers, effective August 7, 2025.

Cingulate Inc. announced the submission of its New Drug Application to the FDA for CTx-1301, its lead asset for ADHD treatment.

Cingulate Inc. reported several unregistered issuances of common stock and option awards between March and July 2025, primarily for services, an officer inducement grant, and conversion of debt.

Cingulate Inc. has entered into a purchase agreement with Lincoln Park Capital Fund, LLC, providing access to up to $25.0 million in common stock sales over a 36-month period to fund its drug development and operations.

Cingulate Inc. announced that its stockholders approved a reverse stock split, an increase in shares for its equity incentive plan, and the re-election of a director at its 2025 Annual Meeting.

Cingulate Inc. terminated a grant agreement with a private family foundation, having received no funds, and will prioritize its lead asset, CTx-1301.